John Militello sold $3,224 of RCKT
See Remarks at ROCKET PHARMACEUTICALS, INC.. 1,060 shares at an average of $3.04, traded Aug 18, 2025, filed Aug 20, 2025.
Score components
- +15RoleOfficer
- 0Trade size$3k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-032092, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2025 | SOpen-market sale Common Stock | -699 | $3.07 | $2,142 | 56,285 | Aug 20, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock | -361 | $3.00 | $1,082 | 55,924 | Aug 20, 2025 |
Related signals
Other insiders at ROCKET PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $256k 75,364 shares | -11% | |
| 15Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $3,862 1,157 shares | -1% | |
| 15Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $12k 3,726 shares | -4% | |
| 35Weak | RCKTbuy ROCKET PHARMACEUTICALS, INC. | Elisabeth Bjork director | $34k 10,000 shares | +25% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $3,240 1,086 shares | -2% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $4,910 1,646 shares | -0% | |
| 40Moderate | ROCKET PHARMACEUTICALS, INC. | Gaurav Shah CEO | $19k 6,276 shares | -1% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Jonathan David Schwartz See Remarks | $7,592 2,545 shares | -1% | |
| 35Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $115k 28,918 shares | -30% | |
| 35Weak | RCKTbuy ROCKET PHARMACEUTICALS, INC. | Elisabeth Bjork director | $34k 10,000 shares | +33% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.